Elagolix reduces menstrual bleeding from most common uterine tumors

A new oral drug significantly reduced menstrual bleeding for women with the most common gynecologic tumors in the United States – benign tumors that disproportionately affect African-Americans, an international clinical trial found.

Go to Source

(Visited 1 times, 1 visits today)

Site Footer

Sliding Sidebar